Senti Biosciences (SNTI) Capital Expenditures (2021 - 2025)

Senti Biosciences has reported Capital Expenditures for 5 years, with the latest figure at $26000.0 in Q2 2025.

• For the quarter ending Q2 2025, Capital Expenditures rose 73.33% year-over-year to $26000.0; the trailing twelve-month figure through Dec 2025 stood at $196000.0 (up 653.85% YoY), and the FY2025 full-year result was $196000.0, up 653.85% from the prior year.
• Capital Expenditures for Q2 2025 stood at $26000.0, down from $170000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $23.5 million in Q3 2022, with the low at -$10.2 million in Q3 2023.
• Average Capital Expenditures over 5 years is $3.3 million, with a median of $1.3 million recorded in 2021.
• Year-over-year, Capital Expenditures surged 3429.32% in 2022 and sank 143.34% in 2023.
• Tracing SNTI's Capital Expenditures over 5 years: stood at $3.3 million in 2021, then soared by 154.94% to $8.5 million in 2022, then slumped by 99.86% to $12000.0 in 2023, then decreased by 8.33% to $11000.0 in 2024, then jumped by 136.36% to $26000.0 in 2025.
• The last three Capital Expenditures figures came in at $26000.0 (Q2 2025), $170000.0 (Q1 2025), and $11000.0 (Q4 2024), per Business Quant data.

Peer Comparison